Dana-Farber Researcher Selected to Join the Pew Scholars Program - Summary - MDSpire

Dana-Farber Researcher Selected to Join the Pew Scholars Program

The Pew Charitable Trusts announced that Xin Gu, PhD, of Dana-Farber Cancer Institute, is among 21 researchers who have been selected to join the Pew Scholars Program in the Biomedical Sciences.

  • By

  • June 18, 2026

  • 2 min

Share

Objective:

To announce the selection of Xin Gu, PhD, as a Pew Scholar in the Biomedical Sciences and outline his research focus.

Approach:
  • Research Focus: Xin Gu will study a newly discovered pathway for selective protein breakdown that regulates gene activity.
  • Techniques Used: Research will utilize cell and molecular genetics, biochemistry, and structural biology.
Key Findings:
  • Xin Gu is among 21 researchers selected for the Pew Scholars Program from over 200 applicants.
  • The program provides four years of funding for innovative research in biomedical sciences.
  • Gu's work focuses on developing strategies for targeting oncogenic gene regulators that were previously considered undruggable.
Interpretation:

Gu's selection highlights the significance of his research in understanding protein balance in cells.

Conclusion:

The Pew Scholars Program supports early-career scientists in advancing biomedical research.

Sources:

Original Source(s)

Dana-Farber Researcher Selected to Join the Pew Scholars Program

  • by

  • June 18, 2026

Related Content

Inside the Rise of circRNA

Circio CEO Erik Wiklund reflects on the discovery of human circular RNA and its evolution into a fast-moving therapeutic modality

  • July 9, 2026

  • 12 min
ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101

A-DREAM/Alliance A032101 study presented by Dana-Farber Cancer Institute's Dr. Atish Choudhury shows 41% of favorable responders to testosterone suppression plus androgen receptor pathway inhibitor remaining treatment-free with testosterone recovery at 18 months after treatment interruption.

  • July 1, 2026

  • 1 min
The importance of robust genomic testing for patients

Misako Nagasaka, MD, PhD shared how precision oncology has fundamentally shifted the landscape through the identification of actionable genomic targets for lung cancer treatment.

  • June 25, 2026

  • 1 min